Brussels, 17/09/2001 (Agence Europe) - At a meeting of the European Parliament's Environment, Health and Consumer Policy Committee on Thursday, MEPs expressed concern at the risks inherent in the use of medicines. They questioned the Executive Director of the European Agency for the Evaluation of Medicinal Products (EMEA), Thomas Lönngren, about the effectiveness of medicines monitoring in Europe. Returning to the cerivastatin affair which was in the headlines this summer and forced Bayer...